Naurex Inc. has presented preclinical data demonstrating that GLYX-13, its rapid-acting novel antidepressant, enhances synaptic plasticity, its hypothesized mechanism of action. The data were presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, FL.

In these studies, GLYX-13 also enhanced enrichment of specific genes associated with synaptic plasticity and long-term depression. GLYX-13 is currently in a Phase IIb repeat-dose trial in patients with depression who experience an inadequate response to their current antidepressants. In an earlier Phase II trial, a single dose of GLYX-13 produced statistically significant and long-lasting reductions in depression scores within 24 hours in patients with major depressive disorder who had failed treatment with one or more antidepressant agents. Data from the Phase IIb trial are expected early in 2014.